<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1A4928A2-632C-49AF-AA0F-66E902DFC05C"><gtr:id>1A4928A2-632C-49AF-AA0F-66E902DFC05C</gtr:id><gtr:name>Oswaldo Cruz Foundation (Fiocruz)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A239A9F-5F48-43FD-A110-9D2BC7E4B9E3"><gtr:id>0A239A9F-5F48-43FD-A110-9D2BC7E4B9E3</gtr:id><gtr:name>Fast Track Diagnostics Ltd.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/690ECCF2-F290-4AE0-82CC-F5507E8EDC7E"><gtr:id>690ECCF2-F290-4AE0-82CC-F5507E8EDC7E</gtr:id><gtr:name>Agency for Science, Technology and Research (A*STAR)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1A4928A2-632C-49AF-AA0F-66E902DFC05C"><gtr:id>1A4928A2-632C-49AF-AA0F-66E902DFC05C</gtr:id><gtr:name>Oswaldo Cruz Foundation (Fiocruz)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A239A9F-5F48-43FD-A110-9D2BC7E4B9E3"><gtr:id>0A239A9F-5F48-43FD-A110-9D2BC7E4B9E3</gtr:id><gtr:name>Fast Track Diagnostics Ltd.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/690ECCF2-F290-4AE0-82CC-F5507E8EDC7E"><gtr:id>690ECCF2-F290-4AE0-82CC-F5507E8EDC7E</gtr:id><gtr:name>Agency for Science, Technology and Research (A*STAR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4EF9783B-547F-4512-B991-889E9DEFD3FE"><gtr:id>4EF9783B-547F-4512-B991-889E9DEFD3FE</gtr:id><gtr:firstName>Girvan</gtr:firstName><gtr:surname>Burnside</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D750E57A-A0D6-4E00-976D-46C8FDC2C014"><gtr:id>D750E57A-A0D6-4E00-976D-46C8FDC2C014</gtr:id><gtr:firstName>Patricia</gtr:firstName><gtr:surname>Brasil</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/449BE192-971D-4090-92D7-79EAC56CE42C"><gtr:id>449BE192-971D-4090-92D7-79EAC56CE42C</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>French</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2D2AADB7-B7B1-4D9F-8954-2565434B64D0"><gtr:id>2D2AADB7-B7B1-4D9F-8954-2565434B64D0</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>Solomon</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/33B43840-A829-4AC9-A982-D74374BB5271"><gtr:id>33B43840-A829-4AC9-A982-D74374BB5271</gtr:id><gtr:firstName>Fernando</gtr:firstName><gtr:otherNames>Augusto</gtr:otherNames><gtr:surname>Bozza</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15096"><gtr:id>098EDB2B-29AD-4BC6-A797-95DE6E466587</gtr:id><gtr:title>Zika: A prospective case-control study to examine the role of Zika virus in Guillain-Barr&amp;eacute;
syndrome in Brazil</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15096</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Guillain-Barr&amp;eacute; Syndrome (GBS) is an acute immune-mediated disease of the peripheral
nervous system which can lead to death or debilitating neurological disability. The number of
GBS cases in Zika-affected areas is rising sharply, but the WHO has urged caution in
attributing them to the virus. Through the Zika Neurology Network, established in 2015, we
will conduct a prospective case-control study of GBS in Rio de Janeiro, focusing on Zika as a
risk factor. The project builds on Liverpool expertise in flavivirus neurological disease, Public
Health England?s diagnostic capabilities, flavivirus research at the Oswaldo Cruz Foundation
(Fiocruz), Rio di Janeiro, and the International GBS Outcome Study?s experience.
We will recruit 60 adults with GBS referred to major hospitals in the Network, with scope to
expand if needed. GBS will be defined through recognised clinical and electrophysiological
criteria, and Zika infection diagnosed with investigations already established at Fiocruz,
including PCR of blood and urine, and IgM and IgG ELISA of blood. Outcome will be assessed
at 2 months. Four community controls will be recruited for each case.
Underpinned by the NIHR Health Protection Research Unit in Emerging and Zoonotic
Infections, which already has team members in Rio supporting protocol, case record form,
and diagnostic developments, the project provides excellent value for money, and is ready to
deliver in a timely manner. Within nine months our study will define the role of Zika as a risk
factor for GBS, to help individual patient management, and importantly to support public
health and policy decisions.</gtr:technicalSummary><gtr:fund><gtr:end>2017-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-31</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>36599</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fast Track Diagnostics Ltd.</gtr:collaboratingOrganisation><gtr:country>Malta, Republic of</gtr:country><gtr:description>Fast Track Diagnostics</gtr:description><gtr:id>176841AC-D694-4ADC-B860-A9DD40D7BC3D</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>545d354dc32835.50360070-1</gtr:outcomeId><gtr:partnerContribution>Development of kits</gtr:partnerContribution><gtr:piContribution>A new partnership where we evalutae new diagnostics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oswaldo Cruz Foundation (Fiocruz)</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Funda&amp;ccedil;&amp;atilde;o Oswaldo Cruz, (FIOCRUZ) collaboration on Zika</gtr:description><gtr:id>8128D8E3-0DA6-490C-B97D-657AC87676AF</gtr:id><gtr:impact>New publications, and grants, see other sections</gtr:impact><gtr:outcomeId>58be8970034ae6.58187771-1</gtr:outcomeId><gtr:partnerContribution>Collaboration on Zika</gtr:partnerContribution><gtr:piContribution>Collaboration on Zika</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Public Health England</gtr:description><gtr:id>7544EBC7-AE9E-4B9B-B951-54252837CDA5</gtr:id><gtr:impact>Lancet ID publication 2010
New National Guidelines
New Programme Grant</gtr:impact><gtr:outcomeId>onFJ56fT8SL-1</gtr:outcomeId><gtr:partnerContribution>Collaborative work on Encephalitis since 2007</gtr:partnerContribution><gtr:piContribution>Collaborative work on Encephalitis since 2007</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Agency for Science, Technology and Research (A*STAR)</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:department>Singapore Immunology Network (SIgN)</gtr:department><gtr:description>A*STAR Singapore</gtr:description><gtr:id>F983AB12-55E7-43C7-AD83-4D3AF0865B93</gtr:id><gtr:impact>Non</gtr:impact><gtr:outcomeId>56e01007aed222.24950206-1</gtr:outcomeId><gtr:partnerContribution>Partnership with Prof Lisa Ng on EV71</gtr:partnerContribution><gtr:piContribution>Partnership with Prof Lisa Ng on EV71</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Published book: Roald Dahl's Marvellous Medicine</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ACE65FA9-1F27-45E0-815C-4DF0B3EB3058</gtr:id><gtr:impact>Popular Science Book, with associated tom radio, newspaper coverage
talks, lectures, schools</gtr:impact><gtr:outcomeId>58be92336ed706.68997817</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.tomsolomon.co.uk</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Union Horizon 2020</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>European Union</gtr:fundingOrg><gtr:id>08D013E9-9630-47FE-9A13-4B0083255205</gtr:id><gtr:outcomeId>58be8a6dbc5cc5.95929971</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>2016-present Member, WHO Consultation on Considerations for Regulatory Expectations of Zika vaccines for use during an Emergency</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8A8B1BB5-EEF0-4E92-AECB-2048FA73E991</gtr:id><gtr:impact>WHO policy on Zika, especially in relation to requirements for vaccine development</gtr:impact><gtr:outcomeId>58c2920245bb41.00403789</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.who.int/immunization/research/development/WHO_UNICEF_Zikavac_TPP_Feb2017.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member, UK Government's Zika Outbreak Precautionary Scientific Advisory Group for Emergencies (preSAGE)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>17B40A5B-817C-47B0-BAB3-2B92681C681E</gtr:id><gtr:impact>Member, UK Government's Zika Outbreak Precautionary Scientific Advisory Group for Emergencies (preSAGE)
Supported policy on travel, risks assessments, developing diagnosis, etc</gtr:impact><gtr:outcomeId>58c2913ceeddb2.56696315</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/584350/160203_PreSAGE_Zika_Minutes_Meeting_1.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BF86FE11-0012-4E70-8ECF-68AB5FDB2D29</gtr:id><gtr:title>ZikaPLAN: Zika Preparedness Latin American Network.</gtr:title><gtr:parentPublicationTitle>Global health action</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1768d63db46fe1232e38d9e98fed07c"><gtr:id>f1768d63db46fe1232e38d9e98fed07c</gtr:id><gtr:otherNames>Wilder-Smith A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1654-9880</gtr:issn><gtr:outcomeId>5a9939cbc49975.32149786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CD0A865-DC4F-4D8E-B2C5-8091830F233D</gtr:id><gtr:title>The spectrum of neurological disease associated with Zika and chikungunya viruses in adults in Rio de Janeiro, Brazil: A case series.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3090473dddbf702dd6b298ee25cdf4e7"><gtr:id>3090473dddbf702dd6b298ee25cdf4e7</gtr:id><gtr:otherNames>Mehta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>5a9939cfd53c08.91139967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF30A787-E439-4AB0-BB75-955DD3B09B57</gtr:id><gtr:title>Global Assessment of Dengue Virus-Specific CD4T Cell Responses in Dengue-Endemic Areas.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34e2a1cee9930c527a685788cf1b8930"><gtr:id>34e2a1cee9930c527a685788cf1b8930</gtr:id><gtr:otherNames>Grifoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a9939cc940a53.54724693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D034441-4E2B-4462-B9BF-E94F8E713148</gtr:id><gtr:title>Structural study of the C-terminal domain of non-structural protein 1 from Japanese encephalitis virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4b48981e45fedc2952dbe8e58b648c5"><gtr:id>a4b48981e45fedc2952dbe8e58b648c5</gtr:id><gtr:otherNames>Poonsiri T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a9939d0240be6.56107418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66414E97-755E-4E2B-8016-7AF8547D6B04</gtr:id><gtr:title>Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34e2a1cee9930c527a685788cf1b8930"><gtr:id>34e2a1cee9930c527a685788cf1b8930</gtr:id><gtr:otherNames>Grifoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a9939cd0ee6d4.99311906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>726C3E17-3A30-4074-A9A9-FC062CC7DCC0</gtr:id><gtr:title>Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/358ab537e0144d3dd636ea6d4483d9fe"><gtr:id>358ab537e0144d3dd636ea6d4483d9fe</gtr:id><gtr:otherNames>Cox JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn><gtr:outcomeId>5a9939cb6916b8.52404579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5C7A6F1-3776-4006-9F83-37F05AA0339E</gtr:id><gtr:title>Zika virus and neurological disease--approaches to the unknown.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d565170e4417b15dd3b581315371bba"><gtr:id>9d565170e4417b15dd3b581315371bba</gtr:id><gtr:otherNames>Solomon T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58ba99f42352e2.63460083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5B8D0CD-805B-45C4-9914-2DA66238C439</gtr:id><gtr:title>A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease.</gtr:title><gtr:parentPublicationTitle>Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2589e0b69b8887580c88c7f00026c23d"><gtr:id>2589e0b69b8887580c88c7f00026c23d</gtr:id><gtr:otherNames>Walker LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1354-750X</gtr:issn><gtr:outcomeId>5a9939cf9a8131.02502417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B63C6E46-1546-4F73-8B90-048988CDB8F2</gtr:id><gtr:title>Guillain-Barr&amp;eacute; syndrome associated with Zika virus infection.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b543485337eb89f8890fd6cdbe92004"><gtr:id>6b543485337eb89f8890fd6cdbe92004</gtr:id><gtr:otherNames>Brasil P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58ba99f3ddd182.56441411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1618B9A1-9FA3-4F9E-8554-FD5FDD3697A3</gtr:id><gtr:title>Challenges of stroke management in resource-limited settings: A case-based reflection.</gtr:title><gtr:parentPublicationTitle>Malawi medical journal : the journal of Medical Association of Malawi</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a8485ebfa54e3677fd2fde6109ddf13"><gtr:id>7a8485ebfa54e3677fd2fde6109ddf13</gtr:id><gtr:otherNames>Gadama YG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1995-7262</gtr:issn><gtr:outcomeId>5a9939cd522a24.34347112</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15096</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes><gtr:rcukProgramme><gtr:id>C11BDEA9-7D9D-4728-B6A9-31032921B328</gtr:id><gtr:text>Newton</gtr:text></gtr:rcukProgramme></gtr:rcukProgrammes></gtr:project></gtr:projectComposition></gtr:projectOverview>